Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Zhittya Genesis Medicine | FGF-1 | Parkinson’s Disease | phase 1 trial initiated in Mexico |
SELLAS Life Sciences Group | GPS | malignant pleural mesothelioma | phase 1 trial enrolling first patient |
CNS Pharmaceuticals WPD Pharmaceuticals |
Berubicin | pediatric brain cancer | phase 1 trial planned in Poland |
Antios Therapeutics | ATI-2173 | hepatitis B | phase 1a trial enrolling 35 patients |
NGM Biopharmaceuticals | NGM120 | cancer and cancer anorexia/cachexia syndrome | phase 1a/1b trial initiated |
Bold Therapeutics | BOLD-100 | gastric, pancreatic, colorectal and bile duct cancers | phase 1b trial initiated in Canada |
Inovio Pharmaceuticals | INO-3107 | recurrent respiratory papillomatosis | IND for phase 1/2 trial granted by the FDA |
Moderna | mRNA-3704 | methylmalonic acidemia | phase 1/2 trial enrolling first patient |
Alkahest | AKST4290 | treatment-naïve neovascular age-related macular degeneration | Phase 2b trial initiated |
Rezolute | RZ358 | congenital hyperinsulinism | phase 2b trial initiated |
Can-Fite BioPharma | Namodenoson | advanced hepatocellular carcinoma | phase 3 trial plan submitted to CHMP |
Plasmology4 | Plaz4 nonthermal plasma technology | multidrug-refractory bacterial and/or fungal pathogen bioburden in a wound bed | Breakthrough Device designation granted by the FDA |
Deciphera Pharmaceuticals | ripretinib | advanced gastrointestinal stromal tumors | priority review granted by the FDA |
Bristol-Myers Squibb | liso-cel | relapsed or refractory large B-cell lymphoma | priority review granted by the FDA |
Eli Lilly | LOXO-292 (selpercatinib) | non-small cell lung cancer | priority review granted by the FDA |
Seattle Genetics | tucatinib | locally advanced unresectable or metastatic HER2-positive breast cancer | priority review granted by the FDA |
Astex Pharmaceuticals | C-DEC (cedazuridine and decitabine) | intermediate- and high-risk myelodysplastic syndrome | priority review granted by the FDA |
GlaxoSmithKline | belantamab mafodotin | relapsed or refractory multiple myeloma | priority review granted by the FDA |
Novartis | capmatinib | non-small cell lung cancer | priority review granted by the FDA |
Kite Pharma | KTE-X19 | relapsed or refractory mantle cell lymphoma in adults | priority review granted by the FDA |
Upcoming Events
-
07May
-
14May